Wire · opportunities
Viking Therapeutics Announces Initiation of VK2735 Oral Maintenance Dosing Clinical Trial ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 6 October 2026 · Fusion42 review
Viking Therapeutics has initiated Part 2 of its clinical trial for VK2735, an oral and subcutaneous dual GLP-1/GIP agonist to maintain initial weight loss in obese patients. This randomized, placebo-controlled study explores multiple maintenance dosing regimens following initial weekly subcutaneous treatment.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You are about to see a shift in obesity treatment with more flexible oral and less frequent dosing options emerging. If you work on metabolic disease therapies, prepare to tailor your product to support patient adherence through diverse dosing regimens.
◆ Coverage
1 source · 6 Oct 2026
◆ Related on Wire
◆ Topics